Lithium bidirectionally regulates depression- and mania-related brain functional alterations without worsening cognitive function in patients with bipolar disorder
Bibliographic Data
| ID | 15517879 |
|---|---|
| Authors | Chuanjun Zhuo (0000-0002-3793-550X, Hangzhou Seventh Peoples Hospital, corresponding author), Guangdong Chen (0000-0001-6252-8562, Hangzhou Seventh Peoples Hospital), Jiayue Chen (0000-0001-6326-903X, Tianjin Medical University), Hongjun Tian (0000-0003-0417-5759, Tianjin Medical University), Xiaoyan Ma (0009-0007-7953-947X, Tianjin Anding Hospital), Qianchen Li (Tianjin Fourth Hospital), Lei Yang (0000-0002-8956-6478, Tianjin Fourth Hospital), Qiuyu Zhang (0000-0002-4823-5031, Tianjin Fourth Hospital), Ranli Li (Tianjin Medical University), Xueqin Song (0000-0001-9830-7155, First Affiliated Hospital of Zhengzhou University, corresponding author), Chunhai Huang (Hangzhou Seventh Peoples Hospital, corresponding author) |
| Year | 2022 |
| Volume | 13 |
| Pages | 963005-963005 |
| Publication date | 2022-09-15 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2022.963005 |
| PMID | 36186884 |
| OpenAlex | W4295926601 |
| Language | EN |
| References cited | 56 |
Lithium monotherapy has been proposed to have antidepressant and antimanic effects in patients with bipolar disorder (BP). However, so far, it is lack of evidence to support this proposition. The main aim of this study was to test the hypothesis that lithium bidirectionally regulates depression- and mania-related brain functional abnormalities in patients with BP. We also assessed the effects of lithium, alone and in combination with other pharmacological treatments, on patients' cognitive performance. We enrolled 149 drug-naïve patients with BP; 99 patients experiencing first depressive episodes were allocated randomly to four treatment groups [lithium (DP/Li), lithium with lamotrigine (LTG; DP/Li+LTG), LTG (DP/LTG), and valproate (VPA) with LTG (DP/VPA+LTG)], and 50 experiencing first hypo-manic episodes were allocated to two treatment groups (MA/Li and MA/VPA). For comparative analysis, 60 age-matched healthy individuals were also recruited. Whole-brain global and regional resting-state cerebral blood flow (rs-CBF) and cognitive alterations were examined before and after 12-week treatment. We have the following findings: DP/Li+LTG, and to a lesser extent DP/Li, alleviated the depression-related reduction in rs-CBF. MA/VPA and MA/Li reversed the mania-related elevation of rs-CBF completely and partially, respectively. Lithium alone improved cognitive performance during depressive and manic episodes; other tested treatments have no such effect or worsened cognitive ability. Our results showed that lithium bidirectionally regulates depression- and mania-associated brain functional abnormalities in patients with BP. Lithium monotherapy has a better antimanic effect than VPA, is superior to other tested treatments in improving cognition during the course of BP, and has satisfactory antidepressant effects in patients with BP
Antidepressant · Bipolar disorder · Depression (economics · Epilepsy · Hippocampus · Lamotrigine · Lithium (medication · Mania · Psychiatry · Bipolar Disorder and Treatment · Electroconvulsive Therapy Studies · Medicine · Pharmacological Effects and Toxicity Studies · Psychology · Internal Medicine
| Citation velocity | historical |
|---|---|
| Highly cited | No |